Management of High-Risk Localised Prostate Cancer

European Urology, Supplements

Volumn 8, Issue 5, 2009, Pages 439-447

  Ozen, Haluk ^a   Yazici, Sertac ^a   Inci, Kubilay ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Definition; High risk; Multimodality approaches; Prostate cancer

Indexed keywords

BICALUTAMIDE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; HYDROCORTISONE; KETOCONAZOLE; LUTEINIZING HORMONE; MITOXANTRONE; MONOCLONAL ANTIBODY; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION RESPONSE; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

EID: 60049096086     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.01.003     Document Type: Review

References (50)

1. Thompson I.M., Carroll P.R., and Carducci M.A. Recommendations for defining and treating high risk localized prostate cancer. J Urol 176 (2006) S6-10
2. Donohue J.F., Bianco Jr. F.J., Kuroiwa K., et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol 176 (2006) 991-995
3. Yossepowitch O., Eggener S.E., Bianco Jr. F.J., et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178 (2007) 493-499
4. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., and Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95 (2005) 751-756
5. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
6. Scardino P.T. Update: NCCN prostate cancer clinical practice guidelines. J Natl Compr Cancer Network 3 Suppl (2005) S29-S33
7. Clark P.E., Peereboom D.M., Dreicer R., Levin H.S., Clark S.B., and Klein E.A. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57 (2001) 281-285
8. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
9. Eastham J.A., Kelly W.K., Grossfeld G.D., Small E.J., and Cancer and Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 62 Suppl 1 (2003) 55-62
10. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21 (2003) 2163-2172
11. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
12. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., and Partin A.W. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176 (2006) 1404-1408
13. Chun F.K., Karakiewicz P.I., Huland H., and Graefen M. Role of nomograms for prostate cancer in 2007. World J Urol 25 (2007) 131-142
14. Kattan M.W., Wheeler T.M., and Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17 (1999) 1499-1507
15. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23 (2005) 7005-7012
16. Greene K.L., Meng M.V., Elkin E.P., et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 171 (2004) 2255-2259
17. Nguyen C.T., Reuther A.M., Stephenson A.J., Klein E.A., and Jones J.S. The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. J Urol 181 (2009) 75-80
18. Carver B.S., Bianco Jr. F.J., Scardino P.T., and Eastham J.A. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 176 (2006) 564-568
19. Bastian P.J., Gonzalgo M.L., Aronson W.J., et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 107 (2006) 1265-1272
20. Freedland S.J., Partin A.W., Humphreys E.B., Mangold L.A., and Walsh P.C. Radical prostatectomy for clinical stage T3a disease. Cancer 109 (2007) 1273-1278
21. Magheli A., Rais-Bahrami S., Peck H.J., et al. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. J Urol 178 (2007) 1311-1315
22. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
23. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006:CD006019.
24. Shelley M.D., Kumar S., Wilt T., Staffurth J., Coles B., and Mason M.D. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 35 (2009) 9-17
25. Wirth M.P., Weissbach L., Marx F.-J., et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 45 (2004) 267-270
26. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781-1788
27. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479
28. McLeod D.G., Iversen P., See W.A., et al. Bicalutamide 150 mg plus standard care vs. standard care alone for early prostate cancer. BJU Int 97 (2005) 247-254
29. Siddiqui S.A., Boorjian S.A., Inman B., Bagniewski S., Bergstralh E.J., and Blute M.L. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol 179 (2008) 1830-1837
30. Saigal C.S., Gore J.L., Krupski T.L., Hanley J., Schonlau M., and Litwin M.S. The Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 (2007) 1493-1500
31. Bolla M., van Poppel H., Collette L., et al. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
32. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329-2335
33. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
34. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25 (2007) 2035-2041
35. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
36. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
37. Bolla M., van Tienhoven G., de Reijke T.M., et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT-results of the randomized EORTC phase III trial 22961. J Clin Oncol 25 Suppl 18 (2007) A-5014 abstract 238s
38. Roach III M., DeSilvio M., Valicenti R., et al. Whole-pelvis, "minipelvis", or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66 (2006) 647-653
39. D'Amico A.V., Manola J., Loffredo M., Renshaw A.A., DellaCroce A., and Kantoff P.W. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 (2004) 821-827
40. D'Amico A.V., Chen M.H., Renshaw A.A., Loffredo M., and Kantoff P.W. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299 (2008) 289-295
41. Pettaway C.A., Pisters L.L., Troncoso P., et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 18 (2000) 1050-1057
42. Febbo P.G., Richie J.P., George D.J., et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11 (2005) 5233-5240
43. Prayer-Galetti T., Sacco E., Pagano F., et al. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 100 (2007) 274-280
44. Kelly W.K., Halabi S., Elfiky A., et al., Cancer and Leukemia Group B. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and CBDCA plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Cancer 113 (2008) 3137-3145
45. Petrylak D.P., Tangen C.M., Hussein M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
46. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
47. Schmidt J.D., Gibbons R.P., Murphy G.P., and Bartolucci A. Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project. Prostate 28 (1996) 51-57
48. Wang J., Halford S., Rigg A., Roylance R., Lynch M., and Waxman J. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 86 (2000) 675-680
49. Kibel A.S., Rosenbaum E., Kattan M.W., et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 177 (2007) 1777-1781
50. Flaig T.W., Tangen C.M., Hussain M.H., et al., Southwest Oncology Group. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 26 (2008) 1532-1536